Stoke Therapeutics (STOK) Liabilities and Shareholders Equity (2018 - 2026)

Stoke Therapeutics' Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $443.3 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 8.94% year-over-year to $443.3 million in Q1 2026; TTM through Mar 2026 was $1.6 billion, a 25.55% increase from a year earlier, with the FY2025 full-year figure at $418.4 million, up 54.09% from the prior year.
• Liabilities and Shareholders Equity advanced to $443.3 million in Q1 2026 per STOK's latest filing, from $418.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $443.3 million in Q1 2026 and bottomed at $205.2 million in Q1 2024.
• The 5-year median for Liabilities and Shareholders Equity is $293.3 million (2024), against an average of $308.8 million.
• Across the five-year window, Liabilities and Shareholders Equity dropped 27.19% in 2024 and soared 98.31% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $256.1 million in 2022, then declined by 10.83% to $228.3 million in 2023, then rose by 18.92% to $271.6 million in 2024, then surged by 54.09% to $418.4 million in 2025, then increased by 5.94% to $443.3 million in 2026.
• Per Business Quant, the three latest STOK Liabilities and Shareholders Equity figures stand at $443.3 million (Q1 2026), $418.4 million (Q4 2025), and $360.3 million (Q3 2025).